Srinivasan Radhika, Gupta Parikshaa, Rekhi Bharat, Deb Prabal, Nijhawan Vijay S, Prasoon Dev, Iyer Venkat, Mathur Sandeep, Gupta Nalini, Kamal Meherbano, Goel Madhu Mati, Chakrabarti Indranil, Jena Madhusmita, Rao Ram Nawal, Rajwanshi Arvind, Raju Siddaraju, Verma Surendra, Pinto Rgw
Indian Academy of Cytologists, India.
J Cytol. 2020 Apr-Jun;37(2):67-71. doi: 10.4103/JOC.JOC_44_20. Epub 2020 Apr 23.
COVID-19, caused by the SARS-CoV-2 virus, has been declared a pandemic by the World Health Organization. This scenario has impacted the way we practice cytopathology. Cytology laboratories receive fresh and potentially infectious biological samples including those from the respiratory tract, from COVID-19 positive or suspected patients. Hence, the Indian Academy of Cytologists thought it necessary and fit to bring forth appropriate guidelines starting from transportation, receipt, processing, and reporting of samples in the COVID-19 era. The guidelines are prepared with the aim of safeguarding and protecting the health care personnel including laboratory staff, trainees and cytopathologists by minimizing exposure to COVID-19 so that they remain safe, in order to able to provide a continuous service. We hope that these national guidelines will be implemented across all cytopathology laboratories effectively.
由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒引起的2019冠状病毒病(COVID-19)已被世界卫生组织宣布为大流行病。这种情况影响了我们进行细胞病理学实践的方式。细胞病理学实验室接收来自COVID-19阳性或疑似患者的新鲜且可能具有传染性的生物样本,包括来自呼吸道的样本。因此,印度细胞学家学会认为有必要且适宜制定在COVID-19时代从样本运输、接收、处理到报告的适当指南。制定这些指南的目的是通过尽量减少接触COVID-19来保障和保护医护人员,包括实验室工作人员、实习生和细胞病理学家,使他们保持安全,以便能够提供持续服务。我们希望这些国家指南能在所有细胞病理学实验室有效实施。